Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had potential to tackle a common superbug that has become resistant to other treatments, The Financial Times’s Hannah Kuchler reports. If successful, it would be the first new class of antibiotic capable of killing acinetobacter or any other “Gram-negative” bacteria to be developed for more than 50 years, the report says. Roche plans to launch a phase 3 trial for zosurabalpin at the end of the year, or early next year, Kuchler writes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Tandem Diabetes, Roche enter patent settlement agreement
- Roche announces EMA’s CHMP has adopted positive opinion for Itovebi
- Genentech announces two-year follow-up data from STARGLO study
- Roche’s Genentech announces FDA approval of Susvimo for diabetic retinopathy
- Trump Trade: White House announces ‘Golden Dome’ missile-defense shield